ClinicalTrials.gg
RecruitingNCT05890573Updated Apr 17, 2024

Efficacy of Bailing Capsule on Pulmonary Fibrosis After COVID-19

An interventional study of Bailing capsule in Pulmonary Fibrosis and COVID-19 Pneumonia, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-04-17.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2024, 2 years 5 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
242
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Pulmonary Fibrosis with a site in China — 14 open to participants now, 18 under way, 4 of them phase 3. Pulmonary Fibrosis · China.

Planned enrollment
12th of 30
242 · median 146
Started
2024
with 3 others
No phase
4 of 40
3 open now
Primary completion
2024-05
later than 1 of 17 live
Registered
21st of 40
by date

Among the 40 studies in Pulmonary Fibrosis with a site in China, this one is the 12th largest by planned enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2024, is one of 4 with no phase, reaches primary completion later than 1 of the 17 other live ones, and was the 21st registered.

Pulmonary Fibrosis

342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.

Browse Pulmonary Fibrosis studies →

Open to participants now

14 of the 40 studies in Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Pulmonary Fibrosis with a site in China, or all of them as a file.
02

Study summary

Pulmonary fibrosis is a sequela of severe infection COVID-19.The prevalence of PCFP ranged from 2% to 45%,and the pathogenesis of PCFP has not been clearly elucidated.The ingredient of Bailing capsule is Cs-C-Q80,it has obvious protective effect on lung.

Studies have shown that Bailing capsule may improve the clinical symptoms of PCPF patients through anti-fibrosis, oxidation and anti-inflammatory effects in multiple pathways.

The purpose of this study was to evaluate the efficacy and safety of bailing capsule in treating PCFP after COVID-19 infection.

Read the detailed description

This is a multicenter, prospective, open, randomized controlled clinical study. Bailing capsule was used for 12 weeks of convalescent treatment in patients with COVID-19 infection to evaluate the efficacy and safety of Bailing capsule on pulmonary fibrosis changes after COVID-19 infection.

The study consisted of a 1-week screening period and a 12-week randomized treatment period.

Screening period (V0) :

All subjects who have signed informed consent will enter a screening period (up to 7 days) to assess eligibility. Subjects with confirmed pulmonary fibrosis changes after COVID-19 infection were required to complete relevant procedures, examinations and assessments according to the study procedure table during the screening period.

Randomized treatment period (V1\~V3) :

The randomized treatment period included V1 to V3 visits. At baseline visit (V1), eligible subjects will be randomly assigned to 6 capsules of Bailing Capsule, tid group, or blank control group in a 1:1 ratio, and receive appropriate treatment during the treatment period:

  1. Experimental group: 6 capsules of Bailing capsule, tid group (n=121), a total of 12 weeks.
  2. Control group: blank control (n=121).

During randomized treatment, subjects will be required to complete procedures, examinations, and evaluations according to the study protocol.

03

Conditions studied

  • Pulmonary Fibrosis
  • COVID-19 Pneumonia

Keywords

  • PCPF
  • COVID-19
  • Bailing Capsule
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-80 years old, gender unlimited;
  2. Fibrous changes in the lungs after COVID-19 pneumonia:

    1. If COVID-19 is positive within the past 2 months, qualitative analysis of SARS-CoV-2 RNA is conducted by antigen detection or PCR detection;
    2. During the screening period, chest HRCT showed the characteristics of pulmonary interstitial lesions (including ground glass shadow, grid shadow, tractable bronchiectasis, septal thickening and early honeycomb shadow, etc.), with fibrosis affected area > 5%;
    3. COVID-19 negative was confirmed during the screening period, and SARS-CoV-2 RNA was qualitatively verified by antigen detection or PCR detection;
  3. Severity grade 2 (moderate) or 3 (severe) according to the mMRC Dyspnea Scale at the screening visit;
  4. Able to perform pulmonary function tests (PFT) and decreased lung function FVC and/or DLCO \<70% of the predicted value at the screening visit;
  5. Able to complete the 6-minute walking test and questionnaire survey;
  6. Fertile female patients must have negative pregnancy test results during screening;
  7. Volunteer to participate in this clinical trial and sign an form.

Exclusion criteria

Exclusion Criteria:

  1. Prior medical history of lung disease (including IPF, bronchial asthma, , lung cancer or pulmonary hypertension) prior to positive diagnosis of COVID-19 pneumonia;
  2. Nephrotic syndrome, moderate to severe chronic renal failure, or \< 60ml/min at enrollment;
  3. Major cardiovascular disease, including chronic heart failure grade III or IV, sinus arrhythmias, ventricular tachycardia, ventricular fibrillation, unstable angina, and severe hypertension (≥160/110 mmHg) that was not under control or was being actively treated within the first 6 months of enrollment;
  4. Screening of patients with abnormal liver function, the criteria are as follows: total > 1.5×; > 3 x ULN; AST > 3 x ULN;
  5. Severe pulmonary arterial hypertension (PAH) meets any of the following conditions:

    1. severe right heart failure in the past;
    2. Cardiac index indicated by right cardiac catheter insertion history ≤2 L/min/m²;
    3. PAH requiring epizoprostol/treprostol parenteral treatment;
  6. Patients with bleeding risk:

    1. Known genetic susceptibility to bleeding;
    2. fibrinolysis, full-dose anticoagulant therapy, or high-dose antiplatelet therapy are required;
  7. Patients had received chest and neck radiotherapy or chemotherapy before screening;
  8. Inability to swallow the study drug;
  9. History of active malabsorption disorders or gastrointestinal resection;
  10. Systemic (e.g. Prednisone, dexamethasone) were administered within 5 days of the first day of administration of the study intervention;
  11. After discharge, take preparations containing cordyceps or anti-pulmonary fibrosis drugs (such as pirfenidone, Nidanib, imatinib, penicillamine, colchicine, tumor necrosis factor α receptor blockers, etc.);
  12. Participation in other clinical trials, use of other drugs or investigational devices within 30 days prior to randomization;
  13. Women or men of childbearing age refuse to use during the study period;
  14. Pregnant or lactating women;
  15. Any other factors that the investigator has determined may be inappropriate for participation in the clinical study;
  16. Patients suffered major trauma or underwent major surgery within 28 days prior to treatment with the study drug;
  17. Other Chinese medicines containing cordyceps were used for treatment within 15 days before and during the study period.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
242 participants (estimated)

Study arms

  • Experimental
    Bailing capsule group

    Bailing capsule group:6 Bailing capsules,po, tid,12 weeks.

    Drug: Bailing capsule

  • No intervention
    Blank group

    Blank group:no anti-fibrosis treatment is given.

Interventions

  • DrugBailing capsule

    6 Bailing capsules,po,tid,12 weeks

06

What researchers measure

Primary outcomes

  1. Rate of clinically significant change in FVC and/or DLCO at Week 12 relative to the baseline value

    Clinically significant changes include a relative ≥ 10% increase in FVC or a relative increase in FVC within the range from ≥ 5% to \<10% and a relative ≥ 15% in DLCO

    Time frame: Week 12

Secondary outcomes

  1. Change in distance covered for 6 minutes (6MWD) from the baseline value (based on 6-minute walk test)

    6MWD changing value

    Time frame: Week 4,Week 8,Week 12

  2. FVC

    FVC(L)changing value

    Time frame: Week 4,Week 8,Week 12

  3. DLCO

    DLCO( mmHg)changing value

    Time frame: Week 4,Week 8,Week 12

  4. FEV1

    FEV1( L)changing value

    Time frame: Week 4,Week 8,Week 12

  5. FEV1/FVC

    FEV1/FVC( %)changing value

    Time frame: Week 4,Week 8,Week 12

  6. TLC

    TLC( L)changing value

    Time frame: Week 4,Week 8,Week 12

  7. The rate of reduction in the lung damage degree based on the high-resolution computed tomography(HRCT) at Week 12 relative to the baseline value

    Classification of lung damage includes the following stages: CT-0 (norm), CT-1 (\< 25% of lung damage), CT-2 (25-50% of lung damage), CT-3 (50-75% of lung damage), CT-4 (\> 75% of lung damage)

    Time frame: Week 12

  8. Change in mMRC Dyspnea Score from the baseline value

    m-MRC changing value

    Time frame: Week 12

  9. Change in the overall score of the SF-36 Questionnaire relative to the baseline value

    36-item Short-Form(SF-36) is a universal scale of life quality developed by Medical Outcomes Study(MOS), which is widely recognized and used in the world. This scale has 8 dimensions to evaluate health-related quality of life (HRQOL), which can be divided into two categories of physiological health and mental health, namely physiological function (PF), role-physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role-emotional (RE) and mental health (MH). 50 is a normal average score, 0 is the lowest, 100 is the highest.The higher the score, the better the health.

    Time frame: Week 12

  10. Change in the overall score of the CQ-11D Questionnaire relative to the baseline value

    TCM Life Quality Evaluation Scale (CQ-11D) is an industry standard document approved and officially released by the China Association of Traditional Chinese Medicine. It is mainly used to evaluate the healthy life quality of the population receiving TCM intervention and the general population, with a total of 11 items. The higher the score, the worse the healthy quality of life status.

    Time frame: Week 12

  11. The rate of adverse events (AEs)

    AE

    Time frame: Week 4,Week 8,Week 12

07

Study locations

1 of 1 sites recruiting
  • Dai Haibin
    Hangzhou, Zhejiang 310009, China
    Recruiting
    • haibin dai · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2024; primary completion for May 2024, 1 month later.

Of 41 interventional studies with no phase under Pulmonary Fibrosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 81. This study's planned 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2023
First posted
Jun 6, 2023
StartEst.
Apr 16, 2024
Primary completionEst.
May 31, 2024
CompletionEst.
Dec 31, 2024
Last update
Apr 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05890573
Responsible party
Sponsor
First posted
Jun 6, 2023
Start date
Apr 16, 2024 (estimated)
Primary completion
May 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Apr 17, 2024

Study contacts

Haibin Dai, Professor
Contact
haibindai@zju.edu.cn
+860571-87783891
Haibin Dai, Professor
principal investigator · Second Affiliated Hospital, School of Medicine, Zhejiang University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion